- Stocks
- Pharma & Healthcare
- Vijaya Diagnostic Centre
Vijaya Diagnostic Centre share price
NSE: VIJAYAPharma & HealthcareDiagnostics & Research
Vijaya Diagnostic Centre at a glance
Vijaya Diagnostic Centre (NSE: VIJAYA) closed at ₹1,382.60 on 22 Oct 2026, up 2.04% on the day. With a market capitalisation of ₹14,324 Cr, it ranks 445th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.
At its last close the stock traded at 82.5× trailing earnings, against a return on equity of 18.1% in FY26. Over the past year the share price has risen 42.1%. Its 52-week range is ₹848.00 (30 Mar 2026) to ₹1,593.60 (23 Sep 2026); the last close is 13.2% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹231 Cr (+22.8% year on year) and net profit ₹53 Cr (+37.6%), on a consolidated basis. Promoters held 52.47% of the company as of 30 Jun 2026; 1.96% of promoter shares were pledged.
Key numbers
- Market cap
- ₹14,324 CrRank 445 on NSE
- P/E (trailing)
- 82.5×
- Price to book
- 9.26×FY26
- EPS (TTM)
- ₹18.23to Q1 FY27
- ROE
- 18.1%FY26
- ROCE
- 19.2%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 21.2%FY26
- Book value / share
- ₹93.02FY26
- 52-week high
- ₹1,593.6023 Sep 2026
- 52-week low
- ₹848.0030 Mar 2026
- 1-year return
- +42.1%
- RSI (14-day)
- 40.5
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +2.04% | −1.5% | −10.6% | +5.5% | +42.1% |
Vijaya Diagnostic Centre quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹183 Cr | ₹169 Cr | ₹173 Cr | ₹188 Cr | ₹202 Cr | ₹205 Cr | ₹219 Cr | ₹231 Cr |
| Revenue YoY | +31.8% | +27.3% | +11.6% | +20.4% | +10.2% | +21.4% | +26.6% | +22.8% |
| Net profit | ₹42 Cr | ₹35 Cr | ₹35 Cr | ₹39 Cr | ₹43 Cr | ₹43 Cr | ₹48 Cr | ₹53 Cr |
| Net profit YoY | +25.5% | +35.8% | +3.5% | +22.5% | +2.8% | +22.3% | +37.5% | +37.6% |
| Net margin | 23.0% | 20.9% | 20.1% | 20.5% | 21.5% | 21.0% | 21.8% | 23.0% |
| EPS | ₹4.09 | ₹3.42 | ₹3.38 | ₹3.76 | ₹4.21 | ₹4.20 | ₹4.66 | ₹5.16 |
Vijaya Diagnostic Centre financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹377 Cr | ₹462 Cr | ₹459 Cr | ₹548 Cr | ₹681 Cr | — |
| Operating profit | ₹112 Cr | ₹147 Cr | ₹114 Cr | ₹161 Cr | ₹194 Cr | — |
| Net profit | ₹85 Cr | ₹111 Cr | ₹85 Cr | ₹120 Cr | ₹144 Cr | — |
| EPS (₹) | ₹8.00 | ₹11.00 | ₹8.00 | ₹12.00 | ₹13.00 | — |
| Cash from operations | ₹130 Cr | ₹158 Cr | ₹165 Cr | ₹183 Cr | ₹224 Cr | — |
| Total debt | ₹3 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹359 Cr | ₹468 Cr | ₹545 Cr | ₹657 Cr | ₹796 Cr | ₹957 Cr |
Vijaya Diagnostic Centre shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 53.05% | 52.63% | 52.60% | 52.60% | 52.51% | 52.47% |
| Foreign institutions | 19.36% | 19.56% | 18.27% | 15.10% | 13.38% | 11.65% |
| Domestic institutions | 23.72% | 24.07% | 25.34% | 28.59% | 29.93% | 31.58% |
| Non-institutions | 3.87% | 3.74% | 3.79% | 3.71% | 4.18% | 4.31% |
| Promoter shares pledged | — | — | — | 1.48% | 1.48% | 1.96% |
Vijaya Diagnostic Centre vs peers
The listed Pharma & Healthcare companies nearest to Vijaya Diagnostic Centre by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SYNGENESyngene International | ₹370.75 | −1.12% | −40.8% | ₹15,037 Cr | 47 | 6.5% |
| AGARWALEYEDr. Agarwal's Health Care | ₹459.10 | −1.51% | −10.7% | ₹14,852 Cr | 100 | 6.6% |
| JUBLPHARMAJubilant Pharmova | ₹930.80 | −0.02% | −13.4% | ₹14,848 Cr | 37.1 | 13.4% |
| POLYMEDPoly Medicure | ₹1,479.10 | +1.31% | −20.5% | ₹14,686 Cr | 46.7 | 10.4% |
| VIJAYAVijaya Diagnostic Centre | ₹1,382.60 | +2.04% | +42.1% | ₹14,324 Cr | 82.5 | 18.1% |
| INDGNIndegene | ₹577.95 | −1.15% | +8.6% | ₹14,171 Cr | 34.8 | 12.8% |
| NATCOPHARMNatco Pharma | ₹785.00 | +0.13% | −3.3% | ₹14,063 Cr | 9.9 | 15.4% |
Ask anything about Vijaya Diagnostic Centre
Pivot answers on the live chart with evidence you can check, and tests strategies against VIJAYA's own history. Try: “Why has VIJAYA moved over the last three months?” · “Backtest a 50-day moving-average crossover on VIJAYA over five years” · “Compare VIJAYA with SYNGENE on margins and valuation”
Frequently asked questions about Vijaya Diagnostic Centre
What is the share price of Vijaya Diagnostic Centre today?
Vijaya Diagnostic Centre (NSE: VIJAYA) last closed at ₹1,382.60 on 22 Oct 2026. Its 52-week high is ₹1,593.60 and its 52-week low is ₹848.00.
What is the market cap of Vijaya Diagnostic Centre?
Vijaya Diagnostic Centre's market capitalisation is ₹14,324 Cr (₹14,324 Cr) at the 22 Oct 2026 close, ranking 445th among the NSE companies Pivot tracks.
What is the P/E ratio of Vijaya Diagnostic Centre?
Vijaya Diagnostic Centre trades at a trailing P/E of 82.5. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 46.7.
What is the ROE and ROCE of Vijaya Diagnostic Centre?
Return on equity was 18.1% in FY26 and return on capital employed was 19.2% in FY26 (consolidated figures).
Is Vijaya Diagnostic Centre a debt-free company?
Vijaya Diagnostic Centre is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Vijaya Diagnostic Centre's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Vijaya Diagnostic Centre reported revenue of ₹231 Cr, +22.8% year on year, and net profit of ₹53 Cr, +37.6% year on year.
How has Vijaya Diagnostic Centre stock performed over the last year?
Vijaya Diagnostic Centre's share price has risen 42.1% over the past year, +5.5% over three months and −10.6% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Vijaya Diagnostic Centre?
As of 30 Jun 2026: promoters 52.47%, foreign institutions 11.65%, domestic institutions 31.58%, non-institutions 4.31%. 1.96% of promoter shares were pledged.
Who are Vijaya Diagnostic Centre's competitors?
The listed Pharma & Healthcare companies closest to Vijaya Diagnostic Centre by market cap are Syngene International, Dr. Agarwal's Health Care, Jubilant Pharmova, Poly Medicure, Indegene and Natco Pharma.
Is Vijaya Diagnostic Centre a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Vijaya Diagnostic Centre's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VIJAYA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with V · all NSE stocks · this page as text